down arrow

Singular Genomics Systems, Inc.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: US82933R1005
USD
20.01
0.05 (0.25%)

Feb 20

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

19.9620.01

52 Week

12.4023.41
Valuation
Technical
Day's Volume

CASH

7.92 k

Shareholding (Sep 2024)

FII

4.34%

Held by 18 FIIs

DII

71.83%

Held by 9 DIIs

Promoter

15.29%

What does Singular Genomics Systems, Inc. do?

22-Jun-2025

Singular Genomics Systems, Inc. is a micro-cap company in the Medical Specialties industry, reporting net sales of $0 million and a net loss of $17 million as of September 2024. Key metrics include a market cap of $50.77 million and a negative return on equity of -70.04%.

Overview: <BR>Singular Genomics Systems, Inc. operates in the Medical Specialties industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Sep 2024) <BR>Market-cap: USD 50.77 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 2,919.01% <BR>Debt Equity: -0.80 <BR>Return on Equity: -70.04% <BR>Price to Book: 0.41<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Singular Genomics Systems, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Singular Genomics Systems, Inc. to determine a bullish or bearish outlook.

As of 1 October 2023, the technical data for Singular Genomics Systems, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Singular Genomics Systems, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Singular Genomics Systems, Inc. is fairly valued with a price-to-earnings ratio of 25.4, competitive against peers like Illumina and Pacific Biosciences, and has shown slight outperformance against the Sensex.

As of 5 October 2023, Singular Genomics Systems, Inc. moved from overvalued to fairly valued. The company currently exhibits a price-to-earnings ratio of 25.4, a price-to-sales ratio of 5.1, and a price-to-book ratio of 3.2. Compared to its peers, Illumina, Inc. has a price-to-earnings ratio of 39.2, and Pacific Biosciences of California, Inc. stands at 15.8, indicating that Singular Genomics is positioned competitively within its industry.<BR><BR>Given these ratios and the peer comparison, Singular Genomics appears to be fairly valued at this time. The recent stock performance has shown a slight outperformance against the Sensex, which further supports the current valuation assessment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Sep 24

  • ROCE(HY) Lowest at -53.57%
  • DEBT-EQUITY RATIO (HY) Highest at -47.2 %
  • RAW MATERIAL COST(Y) Grown by 17.1% (YoY)
2

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 51 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2,919.01%

stock-summary
Debt Equity

-0.80

stock-summary
Return on Equity

-70.04%

stock-summary
Price to Book

0.41

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.7%
0%
-7.7%
6 Months
207.37%
0%
207.37%
1 Year
3682.61%
0%
3682.61%
2 Years
726.86%
0%
726.86%
3 Years
179.08%
0%
179.08%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Singular Genomics Systems, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-28.54%
EBIT Growth (5y)
-244.26%
EBIT to Interest (avg)
-65.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
60.33%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.41
EV to EBIT
0.51
EV to EBITDA
0.55
EV to Capital Employed
-1.87
EV to Sales
-17.73
PEG Ratio
NA
Dividend Yield
2919.01%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-70.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 19 Schemes (8.55%)

Foreign Institutions

Held by 18 Foreign Institutions (4.34%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is -20.00% vs 0.00% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 25.00% vs 5.88% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.40",
          "val2": "-22.70",
          "chgp": "27.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.80",
          "val2": "-22.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44,509.90%",
          "val2": "-53,114.70%",
          "chgp": "860.48%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 262.50% vs 0.00% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -4.29% vs 8.00% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.90",
          "val2": "0.80",
          "chgp": "262.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-93.70",
          "val2": "-87.50",
          "chgp": "-7.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "0.80",
          "chgp": "37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-94.80",
          "val2": "-90.90",
          "chgp": "-4.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34,662.00%",
          "val2": "-122,205.20%",
          "chgp": "8,754.32%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.40
0.50
-20.00%
Operating Profit (PBDIT) excl Other Income
-16.40
-22.70
27.75%
Interest
0.30
0.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.80
-22.40
25.00%
Operating Profit Margin (Excl OI)
-44,509.90%
-53,114.70%
860.48%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2024 is -20.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 25.00% vs 5.88% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
2.90
0.80
262.50%
Operating Profit (PBDIT) excl Other Income
-93.70
-87.50
-7.09%
Interest
1.10
0.80
37.50%
Exceptional Items
-1.90
0.00
Consolidate Net Profit
-94.80
-90.90
-4.29%
Operating Profit Margin (Excl OI)
-34,662.00%
-122,205.20%
8,754.32%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 262.50% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -4.29% vs 8.00% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Singular Genomics Systems, Inc. stock-summary
stock-summary
Singular Genomics Systems, Inc.
Medical Specialties
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."